CoChat

Efficacy of the Telemedical Lifestyle intervention Program TeLiPro in Advanced Stages of Type 2 Diabetes: A Randomized Controlled Trial

Kempf, Kerstin, Altpeter, Bernd, Berger, Janine, Reuß, Oliver, Fuchs, Matthias, Schneider, Michael, Gärtner, Babette, Niedermeier, Katja, Martin, Stephan · 2017 · Diabetes Care
Cited by 159

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Lifestyle interventions are the foundation of treatment in newly diagnosed type 2 diabetes. However, their therapeutic potential in advanced disease stages is unknown. We evaluated the efficacy of the Telemedical Lifestyle intervention Program (TeLiPro) in improving metabolic control in advanced-stage type 2 diabetes. RESEARCH DESIGN AND METHODS: In this single-blind, active comparator, intervention study, patients with type 2 diabetes (with glycated hemoglobin [HbA1c] ≥7.5% [58.5 mmol/mol]), and BMI ≥27 kg/m2 and on ≥2 antidiabetes medications) were recruited in Germany and randomized 1:1 using an electronically generated random list and sealed envelopes into two parallel groups. The data analyst was blinded after assignment. The control group (n = 100) got weighing scales and step counters and remained in routine care. The TeLiPro group (n = 102) additionally received telemedical coaching including medical-mental motivation, a formula diet, and self-monitored blood glucose for 12 weeks. The primary end point was the estimated treatment difference in HbA1c reduction after 12 weeks. All available values per patient (n = 202) were analyzed. Analyses were also performed at 26 and 52 weeks of follow-up. RESULTS: HbA1c reduction was significantly higher in the TeLiPro group (mean ± SD −1.1 ± 1.2% vs. −0.2 ± 0.8%; P < 0.0001). The estimated treatment difference in the fully adjusted model was 0.8% (95% CI 1.1; 0.5) (P < 0.0001). Treatment superiority of TeLiPro was maintained during follow-up (week 26: 0.6% [95% CI 1.0; 0.3], P = 0.0001; week 52: 0.6% [0.9; 0.2], P < 0.001). The same applies for secondary outcomes: weight (TeLiPro −6.2 ± 4.6 kg vs. control −1.0 ± 3.4 kg), BMI (−2.1 ± 1.5 kg/m2 vs. −0.3 ± 1.1 kg/m2), systolic blood pressure (−5.7 ± 15.3 mmHg vs. −1.6 ± 13.8 mmHg), 10-year cardiovascular disease risk, antidiabetes medication, and quality of life and eating behavior (P < 0.01 for all). The effects were maintained long-term. No adverse events were reported. CONCLUSIONS: In advanced-stage type 2 diabetes, TeLiPro can improve glycemic control and may offer new options to avoid pharmacological intensification.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc17-0303

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 12

  1. Esposito, 2009, Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial, Ann Intern Med, 151, 306, 10.7326/0003-4819-151-5-200909010-00004 · DOI · Paper page
  2. Gregg, 2012, Association of an intensive lifestyle intervention with remission of type 2 diabetes, JAMA, 308, 2489, 10.1001/jama.2012.67929 · DOI · Paper page
  3. UK Prospective Diabetes Study (UKPDS) Group, 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
  4. Kempf, 2014, Meal replacement reduces insulin requirement, HbA1c and weight long-term in type 2 diabetes patients with >100 U insulin per day, J Hum Nutr Diet, 27, 21, 10.1111/jhn.12145 · DOI
  5. Kempf, 2012, The Da Vinci Medical-mental motivation program for supporting lifestyle changes in patients with type 2 diabetes, Dtsch Med Wochenschr, 137, 362
  6. Mayer, 2014, Two diets with different haemoglobin A1c and antiglycaemic medication effects despite similar weight loss in type 2 diabetes, Diabetes Obes Metab, 16, 90, 10.1111/dom.12191 · DOI · Paper page
  7. Lage, 2009, Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy, Adv Ther, 26, 217, 10.1007/s12325-009-0002-0 · DOI
  8. Lasa, 2014, Comparative effect of two Mediterranean diets versus a low-fat diet on glycaemic control in individuals with type 2 diabetes, Eur J Clin Nutr, 68, 767, 10.1038/ejcn.2014.1 · DOI · Paper page
  9. Welch, 2015, An internet-based diabetes management platform improves team care and outcomes in an urban Latino population, Diabetes Care, 38, 561, 10.2337/dc14-1412 · DOI · Paper page
  10. O’Connor, 2014, Randomized trial of telephone outreach to improve medication adherence and metabolic control in adults with diabetes, Diabetes Care, 37, 3317, 10.2337/dc14-0596 · DOI · Paper page
  11. Lorig, 2013, Effectiveness of a generic chronic disease self-management program for people with type 2 diabetes: a translation study, Diabetes Educ, 39, 655, 10.1177/0145721713492567 · DOI
  12. Lorig, 2009, Community-based peer-led diabetes self-management: a randomized trial, Diabetes Educ, 35, 641, 10.1177/0145721709335006 · DOI · Paper page

Cited by

See all 159

Metadata

Authors
Kempf, K., Altpeter, B., Berger, J., Reuß, O., Fuchs, M., Schneider, M., Gärtner, B., Niedermeier, K., & Martin, S.
Venue
Diabetes Care
Published
2017-06-13
Volume
40
Issue
7
Pages
863-871
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2613929840
Cited by
159
References
17
FWCI
10.95
Type
journal article
Language
en
Open access
closed
Funders
  • Boehringer Ingelheim International GmbH
  • Gesellschaft von Freunden und Förderern der Heinrich-Heine-Universität Düsseldorf e.V.

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.